The activation of multiple interleukin-1b converting enzyme-related proteases (caspases) in apoptotic mammalian cells raises questions as to whether the multiple active caspases have distinct roles in apoptotic execution as well as how these proteases are organized in apoptotic signaling pathways. Here we used an anity-labeling agent, YV(bio)KD-aomk, to investigate the caspases activated during apoptotic cell death. YV(bio)KD-aomk identi®ed six distinct polypeptides corresponding to active caspases in Fas-stimulated Jurkat T cells. On staurosporine treatment, four polypeptides were detected. Competition experiments showed that the labeled caspases have distinct substrate preferences. Stepwise appearance of the labeled caspases in each cell death event was consistent with the view that the activated caspases are organized into protease cascades. Moreover, we found that stepwise activation of caspases similar to that induced by Fas ligation is triggered by exposing non-apoptotic Jurkat cell extracts to caspase-8 (MACH/FLICE/Mch5). Conversely, CrmA protein, a viral suppressor of Fas-induced apoptosis, inhibited the protease activity of caspase-8. Overall, these ®ndings provide evidence that caspase-8, a CrmA-sensitive protease, is responsible for initiating the stepwise activation of multiple caspases in Fas-stimulated cells.
Introduction
Proteases related to interleukin-1b-converting enzyme (ICE) play pivotal roles in apoptotic cell death (Takahashi and Earnshaw, 1996) . Genetic studies of programmed cell death in Caenorhabditis elegans indicate that a single gene encoding a protease homologous to ICE, ced-3, plays an essential role in all developmental cell death events (Yuan et al., 1993) . In mammalian cells, however, multiple genes encoding ICE/CED-3 family proteases have been cloned. À caspase' nomenclature (for cysteine protease that cleaves after aspartic acid) was recently proposed for human members of this family . The identi®cation of multiple caspases raises several key questions: (i) How many caspases are activated in apoptotic cell death events? (ii) Why are so many proteases activated in the course of apoptosis?
Studies using a cell-free system revealed that multiple caspases are activated in apoptosis (Takahashi et al., 1996a) . Those proteases seem to be required for the cleavage of multiple intracellular proteins, which ultimately causes a sudden collapse into apoptotic death (Martin and Green, 1995) . The dierences in substrate speci®cities among caspases may allow each caspase to play a distinct role in apoptosis by cleaving its own target(s) (Takahashi et al., 1996a) . In support of this notion, while the activity of a lamin-cleaving caspase is required for nuclear fragmentation in the late phase of apoptosis Takahashi et al., 1996b) , the lamin-cleaving caspase alone cannot initiate chromatin condensation and DNA cleavage (Takahashi et al., 1997b) . The coordinated actions of multiple caspases with dierent roles in the execution of apoptosis seem to be required for its characteristic biochemical and morphological changes.
An attractive hypothesis is that caspases may be organized in enzymatic cascades (Martin and Green, 1995; Chinnaiyan et al., 1996b; Fraser and Evan, 1996) . Crystal structures of caspase-1 (ICE) (Walker et al., 1994; Wilson et al., 1994) and caspase-3 (CPP32/Yama/apopain) (Rotonda et al., 1996) suggest that active forms of caspases are tetramers composed of two pairs of large and small subunits, which are derived from two molecules of a precursor by cleavage at multiple Asp-X bonds. This unusual proteolytic processing suggests that caspase activation is driven by autocatalysis, or by cleavage by other caspases (Martin and Green, 1995) . It has also been hypothesized that some caspases are responsible for many of the gross biochemical and morphological changes seen in apoptosis, while others are required to activate the former execution caspases (Kumar and Harvey, 1995) .
The cascade hypothesis is mainly based on demonstrations that recombinant caspases-1, 3, 4, 6/a, and 10 can process precursor(s) of other caspase(s) (Faucheu et al., 1995; Fernandes-Alnemri et al., 1995b Liu et al., 1996; Srinivasula et al., 1996) . However, most of those data were derived from in vitro experiments using recombinant proteins expressed in bacteria, or from analysis of cells in which caspases were overexpressed. The kinetics of the processing of endogenous pro-caspases in Jurkat cells that have internalized granzyme B is dierent from the results obtained when isolated pro-caspases are incubated with the granzyme in vitro . Moreover, even if the pro-caspases are processed to the sizes corresponding to mature forms, it remains to be determined whether the processed procaspases are enzymatically active. For example, the activities of caspases with optimal pH above 6.5 (Pai et al., 1996) may be suppressed as a result of intracellular acidi®cation, which is a common apoptosis-associated event induced by various stimuli .
The presence of a protease cascade has also been suggested by the sequential appearances of proteolytic activities cleaving¯uorescent YVAD and DEVD substrates (Enari et al., 1996) . However, the ability of multiple caspases to cleave YVAD and DEVD tetrapeptide substrates Henkart, 1996) complicates the interpretation of these results. It remains to be determined if each YVAD-or DEVD-cleaving activity in these experiments is due to the activation of a single caspase, or to the activation of multiple caspases. Moreover, even if multiple DEVD-cleaving caspases are organized in a cascade pathway, the existence of the cascade cannot be revealed by such an approach alone.
Here, we investigated the caspases activated in Fasstimulated and staurosporine-treated Jurkat T cells using a powerful tool, the anity-labeling reagent YV(bio)KD-aomk Takahashi et al., 1996a,b) . This reagent covalently binds to the active sites within the large subunits of active caspases (Takahashi et al., 1996a) , selectively labeling processed products having proteolytic activities . Dierences in apparent molecular weight among the labeled proteases enable us to distinguish active caspases from one another (Takahashi et al., 1996a,b) . Time-course studies showed that caspases-3, -7/a (Mch3a/ICE-LAP3/CMH-1), -6/a (Mch2a), and others are activated in a stepwise fashion, suggesting that they are organized into one or multiple protease cascades. In particular, we show that the addition of active caspase-8 (MACH/FLICE/Mch5) to extracts from non-apoptotic Jurkat cells can trigger stepwise activation of caspases that is strikingly similar to that induced by Fas stimulation. Finally, we ®nd that caspase-8 is sensitive to CrmA, the inhibitor of Fasinduced apoptotic cell death (Enari et al., 1995; Los et al., 1995; . Taken together, these results support the notion that the activation of multiple caspases is required for the organization of protease cascades as well as for the cleavage of multiple apoptosis-associated substrates.
Results

Stepwise activation of caspases in apoptotic Jurkat cells revealed by anity-labeling
In the present study, we employed Fas/APO-1 and staurosporine as inducers of two distinct apoptotic cell death pathways. Fas is the cell-surface receptor for Fas ligand and is implicated in various physiological and pathological processes (Nagata and Goldstein, 1995; Abbas, 1996; Boise and Thompson, 1996; Nagata, 1996) . Staurosporine is a broad-spectrum protein kinase inhibitor that is able to induce apoptosis in various types of cells (Bertrand et al., 1994; Jacobson et al., 1996) . Jurkat T cells treated with anti-Fas antibody (Figure 1a ) or staurosporine ( Figure 1b ) underwent apoptotic cell death within a few hours as described previously . Cytoplasmic a b Figure 1 Induction of apoptotic cell death by Fas ligation and by staurosporine. Jurkat T cells were treated with anti-Fas antibody (CH-11, 100 ng/ml) (a) or with staurosporine (1 mM) (b) for the time indicated. The ratio of apoptotic cells were calculated by analysing 100 cells stained with 2 mg/ml DAPI under¯uorescent microscope extracts from the cells were incubated with the anitylabeling reagent YV(bio)KD-aomk to identify the caspases activated therein Takahashi et al., 1996a,b) .
Lysates from Fas-stimulated cells showed the stepwise appearances of six distinct bands over 3 h. We named the labeled polypeptides F25, F22, F20, F19, F17.5 and F17 on the basis of their migration in 16% SDS ± polyacrylamide gel electrophoresis (SDS ± PAGE). , and anity-puri®ed rabbit antiserum against caspase-3-p17 (lowermost lanes). The positions of pro-caspase-3 (p32), caspase-3-p20 (p20), and caspase-3-p17 (p17) stained with antibodies are indicated by arrows
Extracts from staurosporine-treated cells showed a similar but not identical pattern. The four major labeled bands were termed S22, S20, S19, and S17. S22 and S20 started to appear at 30 min (Figure 2d , upper lane 3). S19 and S17 became detectable at 1 h (Figure 2d , upper lane 4; Figure 2c , lane 2). All of these bands had reached their maximum intensity by 2 h and remained unchanged up to 4 h (Figure 2c ). Bands corresponding to F25 and F17.5 were not observed. Otherwise, the order of appearances of labeled species was similar, with 30 min, 1 h, and 2 h of staurosporine-treated cells corresponding to 1 h, 2 h, and 3 h of Fas-stimulated cells, respectively. The relative intensities of labeled species varied as F22, F19 and F17 were relatively weaker than S22, S19 and S17, respectively (Figure 2c , lanes 5 and 6).
Labeling required the addition of YV(bio)KD-aomk ( Figure 3a , lane 1; Figure 3b , lane 1). The labeled polypeptides of M r 17, 20, and 22 kDa were detected at 1 mM of YY(bio)KD-aomk ( Figure 3a , lane 2; Figure  3b , lane 2). Those of M r 19 and 25 kDa required 10 mM for labeling ( Figure 3a , lane 3; Figure 3b , lane 3). In all cases, labeling was potently inhibited by 1 mM DEVD-CHO (Table 1) , an aldehyde derivative of a tetrapeptide that binds with high anity to most caspases (Boldin et al., 1996; Duan et al., 1996b; FernandesAlnemri et al., 1996; Henkart, 1996) . These results indicated that the labeled polypeptides represent active caspases. Also, there are signi®cant dierences in anities for YV(bio)KD-aomk among caspases. It remained to be clari®ed whether caspase(s) exist that have anities too low to be labeled by YV(bio)KDaomk. The protease activity cleaving DEVD-MCA, ā uorogenic substrate for caspases (Boldin et al., 1996; Duan et al., 1996b; Fernandes-Alnemri et al., 1996; Henkart, 1996) , began to rise at 30 min of Fasstimulation, coincident with the appearance of F17.5, and at 30 min of staurosporine-treatment, synchronous with the appearance of S22 and S20 (Figure 4) . Therefore, it was likely that the anity-labeling method resolved the active caspases responsible for the cleavage of DEVD-MCA.
Dierences in substrate recognition properties among activated caspases
We then pursued the possibility that the multiple caspases activated have dierent roles in apoptotic execution. To assess whether the active caspases identi®ed by YV(bio)KD-aomk treatment have different substrate preferences re¯ective of their dierent roles, we evaluated the eects of inhibitors that mimic substrates (Tables 1 and 2 ). First, we tested three tetrapeptide aldehyde inhibitors, YVAD-CHO, DEVD-CHO, and DMQD-CHO, which have been designed based on the sequence within pro-interleukin-1b Cytoplasmic extracts (30 mg total protein) from Jurkat cells treated with anti-Fas antibody for 3 h (F25, F22, F20, F19, F17) or with staurosporine for 2 h (S22, S20, S19, S17), puri®ed His-tagged caspase-3 (215 pg), and E. coli lysates containing caspase-4 (1.2 mg total protein) or caspase-7/a (0.7 mg total protein) were pretreated for 15 min at 378C with DEVD-CHO at concentrations indicated in 10 ml mixtures before labeling with 10 mM YV(bioKD-aomk. +, no inhibition; +*7, 525% inhibition; +, 25 ± 75% inhibition; +*7, 75 ± 99% inhibition; 7, complete inhibition
Affinity-labeling of caspases active in apoptosis A Takahashi et al recognized by caspase-1 (Thornberry et al., 1992) , that within poly(ADP-ribose) polymerase (PARP) recognized by caspase-3 and caspase-7/a (A Takahashi, unpublished observation), and that within protein kinase C d recognized by caspase-3 (Emoto et al., 1995; Datta et al., 1996) . YVAD-CHO up to 100 mM did not aect the labeling of F25, F22, F20, F19, and F17 in cell lysates from Fas-stimulated cells (data not shown). This is consistent with a recent report demonstrating that the protease activity that cleaves YVAD-pNA does not increase after Fas-stimulation of Jurkat cells (Tatsuta et al., 1996) . YVAD-CHO up to 100 mM similarly failed to aect the labeling of S22, S20, S19, and S17 from staurosporine-treated cells (data not shown).
In contrast, DEVD-CHO caused dose-dependent suppression of the YV(bio)KD-aomk binding to active caspases (Table 1) . Interestingly, the labeled caspases showed dierent sensitivities to the inhibitor (F20&F174F224F254F19; S20&S174S224S19). This is consistent with previous studies showing signi®cant dierences in Ki values for DEVD-CHO among caspases (Fernandes-Alnemri et al., 1995b . Then, the eects of DEVD-CHO on the labeling of recombinant caspases were examined for comparison. Caspases-3, -4, and -7/a showed dierent sensitivities to DEVD-CHO; that of caspase-3 was identical to F20, F17, S20 and S17, whereas that of the caspase-7/a was similar to F22 and S22. We could not ®nd any labeled caspases in Fas-stimulated or staurosporine-treated cells having the sensitivity to DEVD-CHO similar to that of caspase-4 (TX/ICH-2/ ICErel-II) ( Table 1) . DMQD-CHO required concentrations at least 100-fold higher than DEVD-CHO to inhibit the caspases activated in Fas-or staurosporinestimulated cells, and showed relative anities to the activated caspases distinct from DEVD-CHO (F204F22&F174F19; S204S22&S174S19) ( Table  2) .
We next analysed the eects of peptides spanning the cleavage site within PARP (Lazebnik et al., 1994) recognized by caspases-3 and -7/a and that within lamin A recognized by caspase-6/a (Takahashi et al., 1996a) . These peptides inhibit PARP and lamin A cleavage, respectively, catalyzed either by recombinant caspases or by caspases present in a cell-free system (Lazebnik et al., 1994; Takahashi et al., 1996a) . The selective anities of the cleavage site peptides for PARP-and lamin-cleaving caspases, showing selective inhibition of YV(bio)KD-aomk-binding to the proteases, have enabled us to identify these caspases in the cell-free system (Takahashi et al., 1996a,b) . PARP peptide had dierent inhibitory eects on the active caspases in Fas-stimulated (F224F174F20&F19; Figure 3c , lane 4) and staurosporine-treated cells (S224S20&S174S19) ( Table 2) . Interestingly, the 
Cytoplasmic extracts (30 mg) from Jurkat cells treated with anti-Fas antibody for 3 h (F22, F20, F19, F17) or with staurosporine (S22, S20, S19, S17) for 2 h were pretreated with inhibitors at concentrations indicated in 10 ml mixtures before labeling with 10 mM YV(bio)KD-aomk. +, no inhibition; +*7, 525% inhibition; +, 25 ± 75% inhibition; +*7, 75 ± 99% inhibition; 7, complete inhibition pattern of sensitivity to the PARP peptide (GDEVD-GIDEV) was not identical to that to DEVD-CHO. It is likely that the additional amino acid residues endow a higher degree of speci®city to the cleavage site peptide. Thus, cleavage site peptides composed of *10 amino acids may be useful reagents that cannot be substituted for by tetrapeptide aldehyde inhibitors. At higher concentrations (3 mg/ml), the PARP cleavage site peptide showed broad spectrum inhibition of all caspases (Table 2 ). This is reminiscent of the ability of caspases other than caspases-3 and -7/a to cleave PARP, albeit with lower eciency (Fernandes-Alnemri et al., 1995a; Gu et al., 1995; Duan et al., 1996b; Muzio et al., 1996) . The lamin A cleavage site peptide preferentially inhibited F19 and S19, with other caspases showing much lower sensitivities (F19»F20&F174F22; S19»S20&S174S22; Figure  3c , lane 2). Changing Asp to Ala within the P1 site markedly reduced the inhibitory eects of both the PARP and the lamin A peptides (Figure 3c , lanes 3 and 5), as previously described (Takahashi et al., 1996a,b) . These dierences in substrate recognition properties suggested by the inhibitor studies agree with the notion that the activation of multiple caspases in each cell death event re¯ects the requirement for multiple proteases with distinct functional roles in the execution of apoptosis (Martin and Green, 1995) .
We also examined the sensitivity to cowpox virus CrmA, a serpin family protein that is able to inhibit various apoptotic cell death events (Takahashi and Earnshaw, 1996) . As shown in Table 2 , CrmA protein had distinct inhibitory eects on the labeled caspases (F19»F20&F174F22; S19»S20&S174S22). It has been reported that Fas-induced apoptosis of Jurkat cells is sensitive to CrmA, whereas staurosporine induces CrmA-insensitive apoptotic cell death in the same cells . However, we could not identify signi®cant dierences in CrmA sensitivity between labeled active caspases in Fasstimulated (F22, F20, F19, F17) and staurosporinetreated (S22, S20, S19, S17) cells. We could not assess the ability of CrmA to inhibit F17.5 or F25, because those caspases were only weakly labeled. Also, it could not be excluded that CrmA blocks Fas-induced apoptosis by inhibiting non-caspase protease(s) .
Identi®cation of YV(bio)KD-aomk-labeled caspases by inhibitor studies F19 and S19 were both inhibited by the lamin A cleavage site peptide and were sensitive to cowpox virus CrmA (Table 2 ). Caspase-6/a, a lamin-cleavage caspase (Takahashi et al., 1996a (Takahashi et al., , 1997a , has been shown to be processed in Fas-stimulated Jurkat cells . Further, the hamster homologue of caspase-6/a is known to be sensitive to cowpox virus CrmA (Liu et al., 1996) . Also, rabbitpox virus CrmA (SPI-2) inhibits the lamin-cleaving caspase in the cytoplasmic extract derived from chicken DU249 cells (Takahashi et al., 1996b) . F19 and S19 showed the lowest sensitivity to DEVD-CHO (Table 1 ) and a previous study indicated that caspase-6/a is not inhibited by DEVD-CHO up to 1 mM . Taken together, these results strongly suggest that F19 and S19 correspond to caspase-6/a.
Immunoblotting using a monoclonal antibody raised against the N-terminal 219 amino acids of caspase-3 revealed an appreciable decrease in pro-caspase-3 after 1 h of staurosporine treatment (Figure 2d , middle lane 4) and the precursor became almost undetectable at 2 h (Figure 2d , middle lane 5). Next, we stained the YV(bio)KD-aomk-labeled caspase-3 blotted onto the nitrocellulose membranes with a rabbit antiserum raised against the large subunit of caspase-3 (caspase-3-p17). The antibody revealed two bands at the positions of S20 and S17 (Figure 2d , lower lanes 4 and 5). S20 and S17 showed similar anities for DEVD-CHO, the PARP and lamin A cleavage site peptides, and CrmA (Tables 1 and 2 ). Recombinant caspase-3 was as sensitive to DEVD-CHO as S20 and S17 (Table 1) . These results strongly suggest that S20 and S17 correspond to the p20 and p17 subunits of caspase-3. The delayed appearance of the p17 subunit is consistent with the slow autocatalytic activity of caspase-3-p20 that cleaves after Asp-29 and yields p17 subunit . Electrophoresis of unlabeled and labeled extracts in the same SDS ± PAGE gel, followed by immunoblotting, showed that the migration of caspase-3-p20 and -p17 was retarded as a result of YV(bio)KD-aomk binding (data not shown). It is of interest that S17 was less sensitive to DMQD-CHO than S20. Loss of the pro-domain in caspase-3-p17 may aect the substrate recognition property of the enzyme. In contrast, processing of pro-caspase-3 in Fas-treated cells was minimal up to 4 h (Figure 2b , middle lanes and data not shown). Staining of YV(bio)KD-aomk-labeled caspase-3 with the rabbit anti-caspase-3-p17 serum detected caspase-3-p20 and caspase-3-p17 that comigrated with F20 and F17 after 2.5 h of Fas-stimulation (Figure 2b , lower lane 5 and data not shown). F20 and F17 had inhibitory pro®les almost identical to S20 and S17 (Tables 1 and 2 ). Thus, F20 and F17 seem to correspond to the minimal amounts of active caspase-3 processed in Fas-stimulated cells. However, the possibility remains that F20 and F17 also contain other comigrating caspase(s).
Identical mobility in SDS ± PAGE gels (Figure 2c , lanes 5 and 6), similar anity for YV(bio)KD-aomk (Figure 3a and b) , and almost identical inhibitory pro®les (Tables 1 and 2) implied that F22 is identical to S22. F22/S22 had the highest sensivitiy to the PARP cleavage site peptide (Tables 2), raising the possibility that it is a major caspase responsible for the cleavage of PARP in apoptotic Jurkat cells. The highest anity for PARP may be advantageous in the competition for the same substrate among multiple caspases. Moreover, recombinant caspase-7/a labeled with YV(bio)KDaomk showed the sensitivity to DEVD-CHO almost identical to F22/S22 (Table 1) . These results strongly suggest that F22/S22 corresponds to caspase-7/a.
Stepwise activation of caspases induced by caspase-8
The stepwise appearances of active caspases with dierent substrate anities supported the existence of protease cascades involving multiple distinct caspases. To address this possibility, we examined whether the addition of a puri®ed active caspase can initiate similar activation of multiple caspases in cell-free extracts. The size of F17.5, the active caspase detected earliest in 
CrmA inhibition of caspase-8 activity
Our results above suggested that caspase-8 is at the pinnacle of an apoptotic protease cascade induced by Fas ligation. It has been reported that Fas-induced cell death is prevented by CrmA (Enari et al., 1995; Los et al., 1995; , in contrast to other cell death events such as staurosporine-induced apoptosis . Interestingly, the protease activity of caspase-8 as assessed by the cleavage of DEVD-MCA (Km *7 mM) was *95% inhibited by preincubation with 100 nM CrmA ( Figure  6a ). In contrast, the cleavage of VEID-MCA, a tetrapeptide¯uorogenic substrate synthesized based on the lamin A cleavage site (Takahashi et al., 1996a) , by puri®ed His-tagged caspase-6/a (Km *120 mM) was only 75% inhibited even with 2 mM CrmA (Figure 6a ). Real time recordings showed that the addition of 100 nM CrmA to the reaction containing 20 mM DEVD-MCA resulted in a time-dependent loss of the protease activity of caspase-8 (Figure 6b ). Addition of saturating levels of DEVD-MCA substrate (200 mM *306Km) did not cause the recovery of protease Five ml of puri®ed His-tagged human caspase-8 dissolved in extract preparation buer (136 ng/ml) was mixed with 1.5 ml of cytoplasmic extracts from normally growing Jurkat cells (37.5 mg/ ml) and incubated for the times indicated at 378C (lanes 2 ± 6). Jurkat extracts (lane 1) and caspase-8 (lane 8) were mixed with 1.5 ml and 5 ml of extract preparation buer, respectively, and incubated for 4 h at 378C. The incubated mixtures were added with 100 mM YV(bio)KD-aomk and treated for 5 min at 378C. (Figure 6b ), indicating that suppression of caspase-8 activity by CrmA is not through a reversible competitive inhibition. The addition of CrmA at 100 nM to the continuously-monitored reaction containing 20 mM VEID-MCA failed to aect the protease activity of caspase-6/a (data not shown).
Cleavage of CrmA by caspase-8
A property shared by serpin family proteins is that they often act as both inhibitors of and substrates for their target protease(s) (Gettins et al., 1993) . Indeed, CrmA is an inhibitor of and a substrate for human and murine caspase-1 (Komiyama et al., 1994; Xue and Horvitz, 1995) . A model has been proposed that the reactive center loop/region of a serpin interacts with the catalytic site of its target protease ®rst, and then the serpin is either cleaved and released from the protease (substrate pathway) or undergoes conformational changes to form a stable inhibitory complex with the protease (inhibitory pathway) (Turner et al., 1995) . We examined the possibility that CrmA inhibits caspase-8 through the same mechanism by checking whether CrmA acts as a substrate for caspase-8. As shown in Figure 7 , puri®ed recombinant human caspase-8 cleaved puri®ed CrmA protein producing a fragment *5 kDa smaller than the uncleaved protein (lane 3). This cleavage was inhibited by 100 mM DEVD-CHO (lane 4), consistent with a proteolytic reaction catalyzed by a caspase. The size of the fragment is compatible with cleavage of CrmA within its C-terminal reactive center loop/region (Komiyama et al., 1994) . Although cleavage of a serpin by a protease does not always signify that the serpin forms a stable complex with the protease (Komiyama et al., 1994) , the cleavage of CrmA by caspase-8 supports a signi®cant interaction between the reactive center region of CrmA and the active site of caspase-8, which can be a basis for transition to the inhibitory pathway (Turner et al., 1995) . Given that saturating levels of DEVD-MCA substrate failed to reverse CrmA inhibition of caspase-8 (Figure 6b ), these results suggested that CrmA inhibits caspase-8 through the mechanism characteristic of serpin family proteins (Gettins et al., 1993) .
Discussion
We used an anity-labeling method to selectively detect activated caspases in cells undergoing apoptosis. It is formally possible that some of the polypeptides labeled with YV(bio)KD-aomk include non-caspase proteins. However, the YV(bio)KD-aomk-labeling was potently inhibited by nanomolar concentrations of DEVD-CHO, an inhibitor of caspases synthesized based on the cleavage site within a death substrate, PARP. Moreover, inhibition studies showed that the labeled polypeptides detected in Fas-stimulated and staurosporine-treated Jurkat cells have signi®cant anities for a panel of caspase inhibitors that mimic death substrates. These included DMQD-CHO, the PARP cleavage site peptide, and the lamin A cleavage site peptide. Furthermore, altering D to A within the PARP and lamin A cleavage site peptides markedly decreased their anities for the YV(bio)KD-aomk-labeled polypeptides. The anity dependent on the presence of Asp residue at P1 site of substrates is characteristic of the caspase family proteases. Based on these results, it was concluded that the anity-labeled proteins detected in the present study represent active caspases. Since precursors and processing intermediates of caspases may have protease activities , the same caspase may generate multiple distinct bands of anity-labeled polypeptides. Indeed, S20 and S17 correspond to caspase-3-p20 and caspase-3-p17, two large subunits of active caspase-3 with dierent degrees of processing. However, no labeled species in the size range expected for pro-caspases were detected in Fas-stimulated or staurosporine-treated Jurkat cells. Further studies are required to delineate whether anity labeling reagents detect pro-caspases or processing intermediates with protease activities in other cell death events and, if detected, what biological relevance those active precursors have in apoptotic processes.
The methodologies used here proved to be eective tools for identifying the caspases activated during apoptotic cell death. A presumptive identi®cation of labeled species corresponding to caspases-3, -6/a, and -7/a was made by combining inhibitor studies and immunoblotting with anti-caspase antibody. Although the weak and variable labeling of F17.5 and F25 precluded their identi®cation by inhibitor studies, the size of F17.5 in accord with that of caspase-8 expected from cDNA (Thornberry et al., 1997) and the ability of caspase-8 to induce active caspases comigrating with those detected subsequent to F17.5 activation (F25, F22, F20, F19, and F17) suggest that F17.5 corresponds to caspase-8. The size of F17.5 is also consistent with that of caspase-10 (Mch4) expected from cDNA (Thornberry et al., 1997) . Caspase-10 has a FADD-like domain similar to caspase-8. Its ability to process pro-caspase-3 and pro-caspase-7/a (FernandesAlnemri et al., 1996) supports the notion that it is one of the apical components of a death cascade composed of caspases. However, caspase-10 was not detected in the death-inducing signaling complex associated with activated Fas receptor (Muzio et al., 1996) . Although the size of caspase-1 expressed in Sf9 cells and labeled with zEK(bio)D-aomk (Martins et al., 1997 ) is similar to that of F25, recent studies detected neither the activity to cleave pro-interleukin-1b nor caspase-1 protein (Schlegel et al., 1996) in anti-Fas-treated Jurkat cells, despite the detection of caspase-1 mRNA in these cells (Alnemri et al., 1995) . The identity of F25 has remained unclear. Our circumstantial evidence, indicating the activation of caspases-3, -6/a, -7/a, and, very likely, caspase-8 in Fas-stimulated cells, suggests that only a subset of the pro-caspases expressed in Jurkat cells are activated in apoptotic events, as shown in a previous study (Martins et al., 1997) . In the present study, the processing of pro-caspase-3 was minimal in Fasinduced apoptosis in contrast to the complete processing in staurosporine-treated cells. This supports the view that dierent protease cascades can be activated by dierent stimuli even in the same cell type (Shi et al., 1996) . Schlegel et al. reported that the processing of pro-caspase-3 begins at 30 min and is completed by 60 min in Fas-stimulated Jurkat cells. However, they used a much higher concentration of anti-Fas antibody (750 ng/ml) (Schlegel et al., 1996) , possibly accelerating the kinetics of early steps in the apoptotic process. Gene knockout studies revealed that PARP cleavage and apoptotic cell death in Fasstimulated thymocytes are not aected by loss of caspase-3 (Kuida et al, 1996) , indicating that the activation of caspase-3 is a dispensable process in the Fas-induced cell death pathway. Staurosporine induced a relatively stronger band comigrating with S17 and a relatively weaker band comigrating with S22 in HL-60 myeloid leukemic cells (data not shown), indicating that the content of activated caspases varies depending on cell types even with the same apoptotic stimulus. These suggested that the relative amount of caspases activated in apoptotic cell death events dier with death-inductive stimuli and cell types.
It seems that the power of the anity-labeling method will yield further insights into the mechanisms of apoptotic cell death by visualizing putative cascade activation of caspases. Here, we demonstrated that the pattern of Fas-induced activation of caspases is recapitulated by exposing extracts from non-apoptotic Jurkat cells to caspase-8. This ®nding seemed more informative than simple demonstrations in vitro that caspase-8 is able to cleave several recombinant procaspases, because it revealed that caspase-8 can activate endogenous pro-caspases in non-apoptotic cell extracts and that the kinetics of caspase activation was strikingly similar to that within Fas-stimulated cells. This is compelling evidence that the engagement of Fas receptors can trigger the full activation of caspases simply by the activation of pro-caspase-8 recruited to the receptors via FADD/MORT1. Furthermore, caspase-8 was potently inhibited by CrmA, which is inhibitory to Fas-stimulated apoptosis of Jurkat cells though not to that induced by staurosporine . This ®nding, in combination with similarities in sensitivity to CrmA of labeled caspases in Fas-stimulated (F22, F20, F19 , and F17) and staurosporine-treated (S22, S20, S19, S17) cells, is consistent with the notion that CrmA inhibition of caspase-8 is responsible for the sensitivity of Fasinduced apoptotic cell death to CrmA (Enari et al., 1995; Los et al., 1995; . Thus, caspase-8, a CrmA-sensitive protease, appears to be critical for the initiation of the protease cascade in Fasstimulated cells. The action of CrmA on caspase-8 may also account for CrmA inhibition of apoptosis induced by tumor necrosis factor (TNF) (Enari et al., 1995; Los et al., 1995; and by a novel death domain-containing receptor, DR3/WSL-1, related to Fas and TNF receptor 1 (TNFR1) . TNF binding to TNFR1 and the activation of DR3 can recruit pro-caspase-8 by forming TNFR1-TRADD-FADD-pro-caspase-8 and DR3-TRADD-FADD-pro-caspase-8 complexes (Boldin et al., 1996; Chinnaiyan et al., 1996a; Fraser and Evan, 1996; Hsu et al., 1996) . Froelich et al. have recently implied that adenovirus-mediated delivery of granzyme B into Jurkat cells induces apoptosis by activating a protease upstream of caspases-3, -6/a, and -7/a. Since granzyme B can cleave and activate procaspase-8 (Muzio et al., 1996) , the authors predict that granzyme B induces apoptosis by activating caspase-8 . Therefore, CrmA may inhibit granzyme B-mediated apoptosis by blocking granzyme B-activated caspase-8 as well as by suppressing granzyme B directly .
A potential limitation of the anity-labeling method is the possible existence of caspases that cannot be labeled by YV(bio)KD-aomk. Indeed, puri®ed active caspase-8 showed only weak labeling with YV(bio)KDaomk, although the presence of mature enzyme was con®rmed by the presence of a protease activity cleaving DEVD-MCA, as well as by the detection of processed subunits by silver staining. In Bcl-2-inhibitable cell death events, including staurosporineinduced apoptosis of Jurkat cells , a caspase that does not interact with YVKD or DEVD peptides may act as an initiator of apoptotic pathways (Susin et al., 1996) . Development of additional anity-labeling reagents based on cleavage sites in apoptotic substrates of caspases (Schlegel et al., 1996; Martins et al., 1997) and combinatory use of several labeling reagents will address these problems. A second factor complicating interpretation of the results of these experiments is the inability to exclude that dierent caspases might migrate indistinguishably close to one another in conventional SDS ± PAGE gels. We are addressing this issue by using techniques with much higher resolution, in particular two dimensional gel electrophoresis (Martins et al., 1997) .
The strategy described here should be a very eective approach for the study of apoptotic cells from species whose caspases have not been cloned or well characterized. Even for human cells, additional caspase family member(s) may remain to be identi®ed (Susin et al., 1996) . The advantage of the anitylabeling method is that the activation of caspases can be displayed even if speci®c antisera recognizing caspases are not available (Takahashi et al., 1996a ). There may not be close parallels between human caspases and that of the other species. Mouse caspase-1 is only 62% identical to human caspase-1 at the amino acid level (Nett et al., 1992; Molineaux et al., 1993) . Only one caspase has been cloned from Caenorhabditis elegans, while ten caspases have been described in human . Still, however, the competition experiments using cleavage site peptides can demonstrate whether functional homologue(s) of human caspase(s) are activated in the non-human cells by showing substrate speci®cities of the labeled caspases (Takahashi et al., 1996a,b) . As additional apoptosis-associated substrates and their cleavage sites are delineated, peptides spanning these cleavage sites can be used as competitors to identify caspase(s) responsible for their cleavage. The approach may turn out to be more fruitful as additional inhibitors with dierent anities for caspases, speci®c ligands such as speci®c antibodies which are able to immunodeplete particular caspase(s), and cells from gene-knockout mice de®cient in particular caspase(s) become available, enabling us to identify each labeled caspase without complicated procedures such as puri®cation of the labeled caspases and microsequencing. Multiple complementary approaches including cloning, gene targeting, biochemical characterization of each caspase, and the detection of activated caspases within cells using speci®c antibodies and anity-labeling reagents, should shed considerable light on the roles of caspases in apoptotic cell death events.
Materials and methods
Reagents
DEVD-MCA, VEID-MCA, 7-amino-4-methyl-coumarin (AMC), YVAD-CHO, and DEVD-CHO were purchased from the Peptide Institute (Osaka, Japan), dissolved in dimethyl sulfoxide (DMSO) at 10 mM and stored at 7808C. DMQD-CHO was custom-synthesized at the Peptide Institute. Monoclonal antibody raised against Nterminal 219 amino acids of caspase-3 was obtained from Transduction Laboratories. Polyclonal rabbit antiserum was raised against the large subunit of caspase-3 (caspase-3-p17) expressed in E. coli and puri®ed using an anity column that consists of caspase-3-p17.
Induction of apoptotic cell death and preparation of cytoplasmic extracts
Jurkat T cells (4610 6 /ml) were treated with 100 ng/ml antiFas antibody (CH-11) (Yonehara et al., 1989) or 1 mM staurosporine (Sigma) for the indicated time periods in serum-free RPMI-1640 (Kikuchi et al., 1995) . Harvested cells were washed once with phosphate-buered saline (PBS), ®xed with 1% glutaraldehyde in PBS, and stained with 2 mg/ml 4',6-diamidino-2-phenylindole (DAPI). Apoptotic cells were counted by analysing the characteristic morphological changes of nuclei by¯uorescence microscopy. Cytoplasmic extracts were prepared by ®ve cycles of freezing, thawing, and grinding (microtube homogenizer, ISO, Japan) of cells in extract preparation buer (Lazebnik et al., 1993 ) (50 ml/10 7 cells), followed by centrifugation for 15 min at 14 000 r.p.m. at 48C to obtain the supernatant.
Anity labeling of active caspases in cell lysates
Cell lysates (20 ± 50 mg total protein) were incubated with indicated concentrations of N-(acetyltyrosinylvalinyl-N ebiotinyllysyl) aspartic acid [(2,6-dimethylbenzoyl) oxy] methyl ketone (YV(bio)KD-aomk) Takahashi et al., 1996a) for 5 min at 378C. The samples were then resolved on 16% SDS ± PAGE gels, transferred to nitrocellulose membranes (Hybond ECL, Amersham), and probed with horseradish peroxidase (HRP)-conjugated streptavidin (Amersham) as described (Takahashi et al., 1996a) .
Preparation of recombinant caspases
cDNAs encoding human caspase-3 (amino acids 29 to 277) (Fernandes-Alnemri et al., 1994) and caspase-6/a (amino acids 24 to 293) (Fernandes-Alnemri et al., 1995a) (kindly provided by Dr Emad S Alnemri) were cloned into the pET-16b vector (Novagen), and the plasmids were transformed into BL21(DE3)pLys (Novagen) E. coli. cDNA encoding Ser-217 through the C-terminus of caspase-8 (MACHa1/FLICE protein) (Boldin et al., 1996; Muzio et al., 1996) was PCR-ampli®ed from human HPB-ALL T cell cDNA library using primers 5'-ACGGGATC-CAGTGAATCACAGACTTTGG-3' and 5'-AGCGTC-GACTCAATCAGAAGGGAAGACAAG-3', cloned into the pCR-II vector by TA cloning (Invitrogen), and con®rmed by sequencing. Caspase-8 cDNA was then excised from the vector with BamHI and Sal I, inserted into the pQE-30 vector (Qiagen), and transformed into M15[pREP4] E. coli. The N-terminal His-tagged caspases-3, -6/a, and -8 were puri®ed from E. coli extracts by anity chromatography with Ni 2+ -NTA agarose (Qiagen) according to the manufacturer's instructions. Human caspase-4 (Faucheu et al., 1995; Kamens et al., 1995; Munday et al., 1995) and caspase-7/a (Fernandes- Alnemri et al., 1995b; Duan et al., 1996a; Lippke et al., 1996) were expressed in DH5a E. coli as full-length proteins fused to glutathione-Stransferase at their N-termini. E. coli lysates containing active proteases were prepared as described (FernandesAlnemri et al., 1995a; Takahashi et al., 1996a) .
Expression and puri®cation of cowpox virus CrmA protein
As has been described (Takahashi et al., 1996b) , the crmA gene was PCR ampli®ed from genomic DNA of cowpox virus using primers RM233 (5'-GGGCCATGGATATCTT-CAGGGAAAT-3') and SM229 (5'-GGACCCGGGTTAA-CAATTAGTTGTTGGAGAGC-3'), and cloned into pTM1-His vector, which had been constructed by inserting the polyhistidine tract coding region of pET-16b (Novagen) into pTM1 plasmid. The crmA open reading frame in the resulting plasmid (pTM1-His-crmA) was veri®ed by sequencing. RK-13 cells were infected with recombinant vaccinia virus generated from pTM1-His-crmA. Finally, the N-terminal (His) 10 -tagged CrmA protein was puri®ed from the cell lysates with His-Bind resin (Novagen), dissolved in serpin solvent (Takahashi et al., 1996b) , and stored at 7808C.
Fluorometric assays for caspase activities
Ten ml of cell lysates, puri®ed caspases, or E. coli lysates containing active caspases were added to 190 ml of reaction buer (100 mM Pipes, pH 7.4, 10% sucrose, 5 mM dithiothreitol, 0.1% CHAPS, 1 mM PMSF, 10% (v/v) aprotinin, 1 mg/ml each of chymostatin, leupeptin, antipain, pepstatin) containing 20 mM of one of two¯uorogenic substrates, DEVD-MCA or VEID-MCA. After incubation at 378C, reactions were stopped by adding 175 ml of 0.2 M glycine-HCl, pH 2.8. Fluorescence was measured by a microplate reader (MTP-100F, CORONA ELECTRIC, Japan) using 360 nm excitation and 450 nm emission ®lters. Concentrations of AMC liberated as a result of cleavage were calculated using standard AMC solutions. The concentration of proteases and substrates were adjusted so that less than 20% of the substrates were consumed during the reactions. It had been con®rmed that the protease activities were proportional to the amount of enzymes added to the reactions. Real-time recordings of the cleavage of DEVD-MCA or VEID-MCA were performed using the reaction buer containing 20 mM substrates as described previously (Takahashi et al., 1997b) . For determination of Km values, the cleavage rate of 1 to 100 mM DEVD-MCA by puri®ed recombinant caspase-8 (2.7 mg) and that of 80 to 300 mM VEID-MCA by puri®ed recombinant caspase-6/a (2.7 mg) were examined by 5 min of real-time recordings. Km values were calculated using the direct linear plot of Cornish-Bowden and Eisenthal (Henderson, 1993) .
Inhibitor studies
Ten ml of cell lysates or solutions containing active recombinant human caspases were preincubated with YVAD-CHO, DEVD-CHO, or DMQD-CHO for 15 min at 378C, with peptides derived from PARP and lamin A cleavage sites (GDEVDGIDEV and RLVEIDNGKQR) for 1 min on ice, or with CrmA protein for 20 min at 378C. Caspase activities in the preincubated mixtures were analysed by labeling with YV(bio)KD-aomk or bȳ uorometric assays.
